Scotiabank Analyst Maintains Buy Rating for Amgen with Target Price $450
Scotiabank analyst Louise Chen has reaffirmed her Buy rating for Amgen (AMGN.US), maintaining a target price of $450.
According to TipRanks data, Chen's success rate over the past year is 53.2%, with an average return of 7.0%.
This means that out of all the ratings provided by Chen in the past year, 53.2% have been successful, resulting in a positive return for the TipRanks' virtual portfolio.